Results 161 to 170 of about 4,852 (207)

Bone Mineral Content, Growth, and Renal Health of Infants With Perinatal Exposure to Maternal Dolutegravir Versus Efavirenz and Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide: The Randomized IMPAACT 2010 (VESTED) Trial

Tapiwa Mbengeranwa, Lauren Ziemba, Sean S. Brummel, Ben Johnston, Haseena Cassim, Gerhard Theron, Zukiswa Ngqawana, Deo Wabwire, Katie McCarthy, John Shepherd, Shahin Lockman, Lameck Chinula, Lynda Stranix‐Chibanda, for the IMPAACT 2010/VESTED study team and investigators   +13 more
openalex   +1 more source

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study

, 2019
Lucia Taramasso, Antonio Di Biagio, Niccolò Riccardi, Federica Briano, Elisa Di Filippo, Laura Comi, S. Mora, Michele Maria Giacomini, Andrea Gori, Franco Maggiolo   +9 more
openalex   +1 more source

Tenofovir Alafenamide Promotes Weight Gain and Impairs Fatty Acid Metabolism-Related Signaling Pathways in Visceral Fat Tissue Compared to Tenofovir Disoproxil Fumarate

Bryan Dulion, Arnold Z. Olali, Niyati Patel, Amarjit S. Virdi, Ankur Naqib, Jennillee Wallace, Ryan D. Ross   +6 more
openalex   +1 more source

Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort [PDF]

Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo, Davide Moschese, Filippo Lagi, Maria Vittoria Cossu, Alessandro Grimaldi, Andrea Giacomelli, Stefano Rusconi, Gaetana Sterrantino, Alberto Borghetti, Spinello Antinori, Cristina Mussini, Simona Di Giambenedetto   +13 more
openalex   +1 more source

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies

Stephanie Cox, Kristen Andreatta, Matthew R. Hendricks, Jiani Li, Alexander Kintu, Lillian B. Brown, Christoph C Carter, Christian Callebaut   +7 more
openalex   +1 more source

Long-term efficacy and safety of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir in treating hepatitis B virus-related acute-on-chronic liver failure: A 144-week data analysis

Yeqiong Zhang, Wenxiong Xu, Zhexuan Deng, Lu Wang, Xingrong Zheng, Xiang Zhu, Xuejun Li, Jianguo Li, Xin Shu, Jing Lai, Liang Peng, Chan Xie   +11 more
openalex   +1 more source

SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS TENOFOVIR ALAFENAMIDE IN THE TREATMENT OF CHRONIC HEPATITIS B: A HOSPITAL-BASED OBSERVATIONAL STUDY

Dr. Bikash Nayak, Dr. Lorika Sahu, Prof. Dr. Rajendra Kumar Panda, Dr. Sourya Mohapatra, Prof. Dr. Umesh Chandra Patra   +4 more
openalex   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Population Pharmacokinetics of Tenofovir Alafenamide Fumarate and Its Metabolite Tenofovir in Healthy Chinese Volunteers

Clinical Pharmacology in Drug Development, 2023
AbstractTenofovir alafenamide fumarate (TAF) is a first‐line drug for treating hepatitis B virus infection. This study aimed to establish the prodrug–metabolite population pharmacokinetic (PK) model for TAF and its metabolite tenofovir (TFV) in healthy Chinese volunteers and evaluate the factors affecting the PK.
Xingfang, Ji, Yunfei, Li, Zhipeng, Wang, Yuan, Gao, Ling, Wang   +4 more
openaire   +2 more sources